2026-08-10 · SEMAGLUTIDE · TopGLP1Providers Data Desk
Compounded semaglutide vs Wegovy: the shrinking gap, honestly priced
The cash-pay gap between FDA-approved Wegovy and verified compounded semaglutide has narrowed to roughly $184–$216 a month. NovoCare↗ sells Wegovy direct at $349 a month standard — $199 for the first two months at starter doses — and the oral Wegovy pill starts at $149. The cheapest verified compounded programs run $133 (Oak Longevity, limited states), $146 (Yucca), $149 (OrderlyMeds↗), and $165 (NexLife↗, dose-flat, no membership). At a $184 monthly difference, the approved product is now within reach of many budgets that once defaulted to compounded.
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
What the extra money buys is not subtle: the exact formulation that produced Wegovy's trial results (roughly 15% average body-weight reduction in STEP-1), FDA manufacturing oversight, pharmacovigilance, and no dependence on the narrowed 503A lane compounded products now occupy. What compounded keeps: a lower floor, dose-flat structures the pen system cannot match, no refill-timing rules, and — at programs like Henry ($149 start) or NexLife — formats like sublingual tablets for the needle-averse, though absorption for those routes is its own evidence question.
Annualized, the decision sharpens. A year of Wegovy at NovoCare's standard rate is $4,188 (less if your first two months catch the intro rate); a year of NexLife's compounded program is $1,980 monthly-billed or $1,740 prepaid; a year at Yucca is $1,752. If insurance covers Wegovy at all, none of these cash numbers matter — and checking is exactly what an insurance-first program like Ro is for. If you are firmly cash-pay, the honest comparison is your dose path through the calculator, plus one non-financial line item: with the gap this small, the premium for the approved product is the cheapest insurance policy in the entire category. The days when compounded semaglutide was a quarter the price of brand are over; decide on the market as it is in 2026, not as it was in 2024.
Not medical advice; whether semaglutide in any form suits you is a clinician's call.